The input provided is a transcript from the podcast This Week in Virology (TWiV), episode 1302, featuring Dr. Daniel Griffin and Dr. Vincent Racaniello.
1. Analyze and Adopt
Domain: Public Health, Infectious Disease (ID) Epidemiology, and Clinical Medicine.
Persona: Senior Medical Policy Analyst & Infectious Disease Specialist.
Tone: Authoritative, evidence-based, clinically rigorous, and objective.
2. Summarize
Abstract:
This clinical update synthesizes the current epidemiological landscape of respiratory and vaccine-preventable diseases as of March 2026. Key focus areas include the escalating economic and clinical burden of measles in the United States, the disappointing results of the STOMP trial for tecovirimat in treating Mpox, and the ongoing zoonotic expansion of H5N1 into marine mammal populations. The discussion further evaluates the 2026-2027 influenza strain selections, the unexpected late-season rise in RSV activity, and the continued high morbidity of COVID-19 in pediatric and geriatric populations. Finally, the update reviews recent clinical trial data for long COVID interventions, specifically noting the lack of efficacy for metformin and UDCA in established post-acute sequelae of SARS-CoV-2 (PASC).
Clinical and Epidemiological Update: TWiV 1302
2:46 Combating Misinformation through Pre-bunking: Highlighting research from Science Advances, the analysts emphasize "pre-bunking" (psychological inoculation) over "whack-a-mole" debunking. Key logical fallacies to identify include the appeal to nature, false dichotomy, ad hominem attacks, common sense fallacies, and post hoc (causation vs. correlation) errors.
9:03 Tecovirimat (TPOXX) Efficacy Failure: The STOMP trial results published in the New England Journal of Medicine indicate that tecovirimat is not effective for Clade II Mpox. Clinical resolution was nearly identical between tecovirimat (83%) and placebo (84%), with no significant difference in pain reduction or viral clearance.
11:35 H5N1 Expansion in Marine Mammals: UC Davis confirmed highly pathogenic avian influenza (HPAI) in seven northern elephant seals in California. This marks the first detection in this species and highlights continued neurological and respiratory threats to marine wildlife.
Cost Analysis: A preprint on medRxiv estimates the cost per measles case at $104,629, projecting a $7.77 billion national burden over five years if MMR coverage continues to decline.
Immune Amnesia: Discussion of a Medscape report regarding "immune amnesia," where measles infection depletes pre-existing immune memory, leaving children 2.7 times more likely to be hospitalized for other infections for up to five years post-recovery.
Elimination Status: Concerns were raised regarding the HHS delay (until November 2026) of the expert meeting to determine if the U.S. has lost its "measles-eliminated" status.
23:21 Influenza Strain Selection (2026-2027): The WHO recommends a complete update of all three viral strains for the next Northern Hemisphere season, including the H3N2 subclade K. The FDA's VRBPAC is scheduled to meet March 12 to finalize U.S. formulations.
25:13 RSV Trends and Diagnostic Utility: RSV activity is unseasonably rising in March. A study in JAMA Network Open confirms that rapid RSV antigen testing in pediatric primary care significantly reduces inappropriate antibiotic prescribing (0.18 vs. 0.29).
27:28 COVID-19 Morbidity Data: CDC data for July 2024βJune 2025 reports 34,000 to 53,000 COVID-related deaths. Risk levels for children under age four remain comparable to adults over 65, despite shifting public health narratives.
Negative Trial Results: A randomized trial in Annals of Internal Medicine found that neither metformin nor ursodeoxycholic acid (UDCA) effectively treated established long COVID symptoms compared to placebo.
Ongoing Trials: The NIH "RECOVER" program is initiating new trials for autonomic dysfunction (POTS) using IVIG and ivabradine, as well as testing GLP-1 receptor agonists and low-dose naltrexone.
RSV Boosters: Currently, there is no official recommendation for a second RSV vaccine dose, as data does not yet show clear incremental benefit.
Pediatric Access (Australia): Discussion of Australian guidelines restricting COVID-19 vaccination in healthy children under 18, contrasting with U.S. "shared decision-making" models.
HPV in Seniors: Analysis suggests theoretical benefits for HPV vaccination in older adults to prevent head and neck cancers, despite standard clinical age limits.